Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women

Απλή σελίδα τεκμηρίου
dc.contributor.authorAthyros, V. G.en
dc.contributor.authorGanotakis, E.en
dc.contributor.authorKolovou, G. D.en
dc.contributor.authorNicolaou, V.en
dc.contributor.authorAchimastos, A.en
dc.contributor.authorBilianou, E.en
dc.contributor.authorAlexandrides, T.en
dc.contributor.authorKaragiannis, A.en
dc.contributor.authorPaletas, K.en
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorTziomalos, K.en
dc.contributor.authorPetridis, D.en
dc.contributor.authorKakafika, A.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorMikhailidis, D. P.en
dc.date.accessioned2015-11-24T19:35:18Z
dc.date.available2015-11-24T19:35:18Z
dc.identifier.issn1875-6212-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23694
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectCardiovascular Diseases/etiology/*prevention & controlen
dc.subjectCholesterol, LDL/blood/*drug effectsen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHeptanoic Acids/*therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useen
dc.subjectMaleen
dc.subjectMetabolic Syndrome X/complications/*drug therapyen
dc.subjectMiddle Ageden
dc.subjectProspective Studiesen
dc.subjectPyrroles/*therapeutic useen
dc.subjectRisk Factorsen
dc.subjectSex Factorsen
dc.titleAssessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and womenen
heal.abstractAIM: To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years. PATIENTS-METHODS: This prospective, randomized, target driven study included 1,123 subjects (512/611 men/women, aged 45-65 years) with metabolic syndrome (MetS) without diabetes or CVD referred to specialist outpatient clinics. Patients were randomized to two treatment groups: group A with low density lipoprotein cholesterol (LDL-C) target of < 100 mg/dl and group B with a target of < 130 mg/dl. Atorvastatin was used in both groups on top of optimal multifactorial treatment, (quinapril, amlodipine, hydrochlorothiazide for hypertension, metformin for impaired fasting glucose, and orlistat for obesity). The e-CVD risk was calculated using the Framingham, the PROCAM and Reynold's equations. RESULTS: Reductions in e-CVD risk at 6 months were > 50%in all patients, but were superior in group A and in women. Reductions were even greater during the next 3-years and were mainly attributed to changes in lipid profile. Actual CVD events were 1 in group A and 13 in group B; p=0.0012. CONCLUSIONS: Attaining the treatment target of LDL-C < 100 mg/dl within multifactorial treatment of MetS by expert clinics, is achievable and beneficial even in patients without diabetes or known CVD. This induces a considerable e-CVD risk reduction in MetS patients. Actual CVD events were negligible, suggesting that e-CVD risk overestimates actual CVD risk in MetS, at least in patients achieving LDL-C < 100 mg/dl [ClinicalTrials.gov ID: NCT00416741].en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21476961-
heal.journalNameCurr Vasc Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ